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Abstract 9 
Complex engineered nanoparticles (CENPs), which have different core and surface components, are being 10 
developed for medicinal, pharmaceutical and industrial applications. One of the key challenges for 11 
environmental health and safety assessments of CENPs is to identify and quantity their transformations in 12 
biological environments. This study reports the effects of in vivo exposure of citrate-coated nanoalumina 13 
with different rare isotope labels on each component. This CENP was dosed to the rat and accelerator 14 
mass spectrometry (AMS) was used to quantify 26Al, 14C, and their ratio in the dosing material and tissue 15 
samples. For CENPs detected in the liver, the rare isotope ratio, 14C/26Al, was 87% of the dosing 16 
material’s ratio. The citrate coating on the nanoalumina in the liver was stable or, if it degraded, its 17 
metabolites were incorporated with nearby tissues.  However, in brain and bone where little alumina was 18 
detected, the rare isotope ratio greatly exceeded that of the dosing material. Therefore, in the animal, 19 
citrate dissociated from CENPs and redistributed to brain and bone. Tracking both the core and surface 20 
components by AMS presents a new approach for characterizing transformations of CENP components in 21 
biological milieu or environments.  22 




• The core and coating components of engineered nanoparticles were labeled with rare isotopes. 24 
• These complex nanoparticles were injected into the rat. 25 
• Dose and tissue samples were analyzed for both rare isotopes. 26 
• The rare isotope ratio (14C/26Al) demonstrated the relative stability of the two CENP components 27 
 28 
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1. Introduction 32 
Complex engineered nanoparticles are being developed for a variety of applications such as 33 
biomacromolecule receptors [1], biosensors [2], imaging indicators [3] and drug carriers [4]. The core 34 
nanoparticles include the metal oxides, such as alumina (Al2O3) [5]; ceria (CeO2) [6, 7]; titania (TiO2) [8]; 35 
zirconia (ZrO2) [9]; and carbon-based nanomaterials, such as non-functionalized graphene [10, 11], single, 36 
and multi-walled carbon nanotubes [10, 12]. These core materials have extremely low aqueous solubility 37 
and therefore persist in biological media with potential to cause delayed toxicity [13-16]. In previous 38 
studies, we have found that, in the rat, a single intravenous administration of 30 nm ceria engineered 39 
nanoparticles distributed to specific organs within 24 hours; the ceria levels in these organs did not 40 
significantly decrease up to 90 days [17]. The coating materials, such as organic acids, silane coupling 41 
agents, proteins, or polymers, can control the dispersion and agglomeration of nanoparticles in fluids; they 42 
can also interact with solids and solutes in organisms and in the environment [11, 18, 19]. Citric acid, a 43 
tridentate carboxylic acid, has been widely applied on stabilizing metal oxide nanoparticles [20, 21]. The 44 
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fate of the citrate coating on these nanoparticles was not known. Therefore, the fate and toxicology of 45 
CENPs in biological media depends not only on the physico-chemical attributes of the core nanoparticle 46 
(size, size distribution, shape), but also their surface-bound molecular coatings. Material balances need to 47 
be performed on both the core and coatings materials in order to properly interpret their transport and 48 
transformations over the product life cycle.  49 
The common characterization methods for bio-distribution and bio-persistence of CENPs are high-50 
resolution transmission electron microscopy (HR-TEM) [22] and inductively coupled plasma mass 51 
spectrometry (ICP-MS) [23, 24]. The former can give good morphology information but may not provide 52 
sufficient chemical analysis. The latter provides good inorganic chemistry information but may not 53 
provide sufficient analysis of organic components. Some methods based on radioactive isotopes have been 54 
proposed. Perez-Campana et al. [25] utilized 13N-labeled nanoalumina formed by proton beam activation 55 
to show bio-distribution in different organs. It verified that nanoalumina accumulated in the liver. As the 56 
half-life of 13N is 9.97 min, it is useful for short time periods only. Rojas et al. [26] used the 18F isotope to 57 
label the amino coating on ceria nanoparticles and showed that ceria accumulated mainly in lungs, spleen, 58 
and liver. However, labeling only one component of CENPs is not enough; the components might 59 
differentially dissociate, degrade, or transport in biological media.  60 
Therefore, we used one isotope tracer for the core material and another for the coating material. 61 
Accelerator mass spectrometry (AMS), the most sensitive form of isotope ratio mass spectrometry, was 62 
used to characterize the two tracers. The AMS ion source produced negatively charged cesium ions to 63 
sputter the surface atoms of samples. A beam of negative ions, some of which were the radioactive tracer, 64 
were produced, and then accelerated to very high speed in a tandem accelerator. At the positive terminal 65 
of the tandem accelerator, the negative ions will undergo recharging to positive via a gas or carbon foil 66 
electron stripper,. Almost all molecular ions were dissociated in the procedure, since a beam with a 67 
positive charge of 4 or greater is typically selected (i.e. at least 5 electrons are removed) and molecular 68 
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ions dissociate. The ions of the rare isotope were easily selected using electric and magnetic fields and 69 
counted using  nuclear detection techniques. One of the abundant stable isotopes is measured on the high 70 
energy side of the accelerator (after destruction of interfering molecular isobars) in a faraday cup and this 71 
provides the second part of the ratio (oftentimes denoted as rare/stable) [27, 28]. Therefore, this analysis 72 
tool can separate rare isotopes with high selectivity and sensitivity, detecting such species at levels 103 to 73 
109 times lower than other methods [29, 30]. It has been applied in pharmaceutical and toxicological 74 
studies to investigate metabolism of drugs [31], covalent bonding of metabolite to RNA/ protein [32] and 75 
imaging of radioactive label [33, 34].    76 
[This is not a complete sentence]Using AMS techniques to find and quantity low levels of complex 77 
nanoparticle components in biological systems where transporting or transformations might take place. 78 
Moreover, it should be possible to identify changes in the molar ratio (coating:core) after biological 79 
exposures of CENPs. Dual tracer technology should provide an understanding of the biodistribution and 80 
transformation of CENPs in various milieus. In this study, nanoalumina was used as the core material. It 81 
has very low solubility in aqueous systems and is relatively common in the environment; it has potential 82 
to enter biological tissue and persist there. The nanoalumina was synthesized using a hydrothermal 83 
system. 26Al was introduced in the synthesis as the core material tracer. Hydroxyl groups on the 84 
nanoalumina surface can react with 14C-labeled citric acid, used as a coating material. The citric acid was 85 
either covalently bound to the nanoparticle or self-crosslinked on the surface. The CENP, 26Al-labeled 86 
nanoalumina core with 14C-labeled coating, was infused into rats. The dosing material and selected tissues 87 
were analyzed by AMS in Purdue Rare Isotope Measurement Laboratory (PRIME lab) to quantify 26Al 88 
and 14C.  89 
 90 
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2. Experiments 91 
2.1 Synthesis of neat nanoalumina  92 
The synthesis route was modified from Chuah’s work [35]. 0.001 mol of anhydrous aluminum chloride 93 
(AlCl3, Acros) was dissolved in 10 mL 1 M HCl solution to form 0.1 mol/L AlCl3 solution. Anhydrous 94 
AlCl3 has a very high tendency to hydrolyze so it was dissolved in an acidic solution at a pH of about 2.5 95 
to avoid precipitation. 1 mL 26Al-HCl solution (16.5 nCi/mL, provided by the PRIME Lab) was diluted 96 
10-fold. 600 μL of the diluted solution (1 nCi 26Al) was added to the AlCl3 solution. 0.5 M NaOH solution 97 
was added dropwise into the aluminum chloride solution with stirring until the pH was 9.5. AlO(OH) and 98 
Al(OH)3 are formed in the process (scheme 1).  99 
AlCl3 +3NaOH→AlO(OH)+3NaCl+H2O  100 
   AlCl3 +3NaOH→Al(OH)3+3NaCl                                            Scheme 1 101 
The obtained white opaque mixtures were transferred to PTFE containers. The containers were inserted 102 
into a metal container (Parr Instrument Company, Models 4746). They were put in a furnace at 190 °C for 103 
24 h, and then cooled to room temperature. The products were washed with distilled water three times and 104 
ultracentrifuged to remove the remaining Al3+ ion. The solid samples were dried at 90°C for 2 h to remove 105 
the adsorbed water and then heated to 600°C for ½ h. The AlO(OH) and Al(OH)3 nanoparticles 106 
decomposed to form γ-alumina nanoparticles via calcination (scheme 2) [36].  107 
2AlO(OH) → Al2O3+H2O           108 
2Al(OH)3 → Al2O3+3H2O         Scheme 2 109 
The final samples were named “neat nanoalumina”. The weight was 40 mg, 80% of the expected product 110 
mass. The expected radioactivity was 26Al 0.02 nCi/mg. 111 
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2.2 Formation of citrate-coated nanoalumina 112 
For coating nanoalumina with citric acid, 400 mg citric acid (MW=192, citric acid: alumina=10:1 w/w) 113 
was dissolved in 4 mL water. 50 μL citric acid with 14C (0.05 mCi/mL, Amersham Bioscience UK limited, 114 
CFA263) was diluted into 5 mL, to 0.5 μCi/mL. 500 μL of this diluted solution (250 nCi 14C) was added 115 
to the citric acid solution. Thermo-gravimetrical analysis showed that the adsorbed citric acid was 0.32% 116 
of that added. The adsorbed 14C citric acid should have 0.8 nCi if the adsorbed/total ratio didn’t change. 117 
40 mg of neat nanoalumina was added to the citric acid solution, then the mixture was stirred for 24 h. The 118 
sample was washed by distilled water, ultracentrifuged and recovered three times to remove the free citric 119 
acid, and then was dried at 90 °C for 2 h. The dried sample was named “citrate-coated nanoalumina” with 120 
an expected radioactivity of 0.02 nCi/mg.  121 
2.3 Characterization of nanoalumina 122 
The shape and morphology of neat nanoalumina were observed by scanning electron microscopy (SEM, 123 
Hitachi 4300, University of Kentucky). Quantitation of hydroxyl and citrate groups on the surfaces of neat 124 
and citrated-coated nanoalumina was done via thermo gravimetric analysis (TGA) (Perkin Elmer, TGA-7 125 
Thermo gravimetric Analyzer). In a nitrogen environment, the neat and citrate-coated nanoalumina were 126 
heated from room temperature to 110 °C, kept at 110 °C for ½ h to remove physically-adsorbed water, 127 
then heated to 750 °C at a rate of 10 °C/min. Within the higher temperature range, hydroxyl groups at the 128 
metal oxide surface will dehydrate to form water and the citrate coating will decompose to form carbon 129 
dioxide and ethylene [37]. To analyze the ability  of citrate coating to create astable dispersion, some neat 130 
and citrate-coated nanoaluminas were dispersed in water with ultrasonication. The particle distribution in 131 
the dispersion was measured by dynamic light scattering (90 Plus, particle size analyzer, Brookhaven 132 
Instrument Corporation). 133 
2.4 Animal infusions  134 
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20 mg of the citrate-coated nanoalumina was put into 1 ml water then ultrasonicated; the dispersion was 135 
expected to have 0.4 nCi 26Al and 0.4 nCi 14C/ml. One rat was intravenously infused, via a cannula 136 
inserted into a femoral vein that terminated in the vena cava, with 0.4 ml of this dispersion (anticipated 137 
dose 0.16 nCi 26Al and 0.16 nCi 14C).  The dosed animal was terminated 30 days later and tissues, 138 
including liver, brain, and bone, were collected. The similar tissues from one un-dosed rat were collected 139 
as the control samples.  140 
2.5 Sample preparation and AMS quantification of 26Al  141 
The pathways to analyze 26Al and 14C are described in the following paragraphs and summarized in 142 
Scheme-3 and Scheme-4.  143 
To quantify 26Al in the dosing material, it was diluted 100-fold to form a 0.2 mg/mL dispersion. 400 µL of 144 
the commercial analytical standard Al in HCl solution (Aluminum Standard for ICP, 10,000 mg/L in 5% 145 
nitric acid, 41377 Fluka) was added to two 10 µL aliquots of the diluted dosing material (Al2O3-1 and 146 
Al2O3-2). This enabled determination of the 26Al/27Al ratio by introducing a known amount of 27Al (4 mg) 147 
that greatly exceeded the 27Al in the sample. This was done to provide enough material for the AMS 148 
measurement. The two samples were then dried and ashed at 1000 °C.  149 
To quantify 26Al in tissue samples, each sample (from the dosed and control animals) was transferred to a 150 
scrupulously cleaned, pre-weighed, 7-ml Teflon screw-cap container and re-weighed to obtain sample 151 
weight. Four mg of 27Al from the standard HCl solution was added to each sample. The mixture was dried 152 
at 110 °C. 3 ml 2:1 v/v mixture of HNO and H2O2 was added to digest the samples. After evaporating the 153 
liquid using a heatable, semi-closed system [38], the samples (except brain samples) were ashed at 154 
1000 °C. For brain samples, direct ashing will result in some glasslike material believed to be aluminum 155 
oxyphosphate. A procedure that separates Al from phosphate was used [39]. A diluted mixture of HNO3 156 
and H2O2 was used to solubilize the residue after evaporating the liquid. Two grams of cation exchange 157 
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resin containing a sulfonic acid functional group (AG 50-X8, 100-200 mesh; Bio-Rad) was used to 158 
complex the Al3+. After washing three times with 5 mL 0.2% HNO3, 5 mL of 1M hydrofluoric acid (HF) 159 
was used to elute Al from the resin. The solution was dried by evaporation then ashed at 1000 °C. The 160 
dosing material and tissue samples were sent to the PRIME lab for 26Al quantification by AMS. Upon 161 
receipt at the PRIME Lab, the samples were mixed with Ag in an approximately 2:1, Ag:Al2O3 weight 162 
ratio. After mixing, the sample was inserted into a cavity in a sample holder (cathode) that was 0.040” in 163 
diameter and 0.080” deep. The silver greatly increases the current out of the cesium sputter source and 164 
increases efficiency of the measurement. The cathode was inserted into the PRIME Lab ion source. A 165 
typical sample will produce a current of 500 nA in the source which translates to a count rate of 166 
approximately 25 counts per minute for a sample with a 26Al/27Al ratio of 10-12. Standards of known value 167 
were measured before and after the assay of the unknowns and were used to normalize the ratios. Samples 168 
were typically measured until they were used up or a precision of 3% was achieved.   169 
 170 
2.6 Sample preparation and AMS quantification of 14C 171 
To quantify 14C in the dosing material, it was diluted 10-fold to form a 2 mg/mL dispersion. Three 10 µL 172 
aliquots of the diluted dispersion were collected (CA-1, CA-2 and CA-3). The CA 1-3 samples were sent 173 
to the PRIME lab. For the dose material dilutions, tributyrin was added directly to the sample. Tributyrin 174 
has no vapor pressure to speak of and is carbon rich. The 14C:12C ratio of the tributyrin is almost exactly 5 175 
x 10-14. The mixture was placed in a small quartz tube that was nestled in a Pyrex tube with a glass 176 
microfiber filter in the top. The Pyrex tube was then placed in a centrifuge tube with another glass 177 
microfiber filter in the top. The lid of the centrifuge tube had a few small holes drilled for water vapor 178 
removal. This apparatus was then placed in a centrifuge and spun under vacuum for 24 h to remove the 179 
water. The sample was then placed in a combustion tube with appropriate reactants, pumped to less than 180 
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15 microns as recorded by a gauge on the vacuum line. The tube was sealed with a torch, and placed in an 181 
oven to be combusted. The CO2 was then transferred to another tube and graphitized using the method 182 
developed by Ognibene et.al [40].  183 
The tributyrin method was good for the dosing material, since it had a very low content of carbon 184 
material. There was not enough material for an accurate AMS measurement without addition of a carrier. 185 
However, the tissue samples provide sufficient carbon content to permit direct measurements of the 186 
14C/12C ratio without addition of a carrier. The tissue sample was located in a combustion tube with 187 
appropriate reactants, the tube sealed with a torch, and the contents combusted, as above. The CO2 was 188 
then transferred to another tube and graphitized as above. After graphitization, the sample was transferred 189 
into an aluminum sample holder (cathode) and pressed into a 0.040” diameter hole that was 0.040” deep. 190 
The sample holder was then placed into the PRIME Lab ion source (reference below) which typically 191 
generates 13C-currents of 500-750 nA with the corresponding 14C4+ ion detection rates of about 200 Hz for 192 
a sample 14C-enrichment of about 2 x 10-12 of total carbon. The 14C/12C ratios were analyzed with no δ13C 193 
correction. Standards of known ratio are constantly measured to normalize the values of the unknown. 194 
Samples were typically measured until they were used up or a precision of 1% was achieved.  195 
 196 
Ion source reference (can be used for both the aluminum and carbon AMS part): G.S. Jackson, D. Elmore, 197 
M. Caffee, K.A. Mueller, B. De Bonte, P. Muzikar, B. Alexander, Nuclear Instruments and Methods in 198 
Physics Research Section B: Beam Interactions with Materials and Atoms 223-224 (2004) 155. 199 
 200 
3. Results and Discussion 201 
3.1 Particle size analysis 202 
AMS detection of CENPs 
10 
 
Figure 1 shows the morphology of neat nanoalumina. The top surfaces of most nanoalumina were square. 203 
It is not very easy to determine if they were cubic or square disks. The typical particle size was 50 to 80 204 
nm. However, some smaller (30 nm) and larger particles (100 nm) existed, which may come from 205 
sintering and Ostwald ripening in the hydrothermal and calcination processes. Figure 2 shows the volume-206 
averaged particle size distribution of neat and citrate-coated nanoalumina in their dispersion. The 207 
dispersion of neat nanoalumina showed three peaks: one centered at 95 nm (65 nm < D < 180 nm); one 208 
over the range, 230 nm to 500 nm; and one over the range, 1 µm to 2 µm. The peak centered at 95 nm was 209 
consistent with the size observed in SEM. The larger peaks likely represent agglomerates. The dispersion 210 
of citrate-coated nanoalumina showed only two peaks: one over the range of 65 to 105 nm with a peak at 211 
83 nm and a second over the range, 230 to 360 nm. No larger agglomerates were observed. The results 212 
shows the citrate coating helped stabilize the dispersion of nanoalumina.  213 
3.2 Thermogravimetric analysis of nanoalumina 214 
Figure 3 shows the TGA curves of neat and citrate-coated nanoalumina. The weight of the neat 215 
nanoalumina decreased 0.68% due to the loss of surface hydroxyls. Based on a method to estimate surface 216 
density of functional groups [24], the sample had a surface density of 17 hydroxyl groups/nm2, assuming 217 
an average particle was a 60 nm cube. For the citrate-coated nanoalumina, the weight loss was 3.85%. The 218 
3.2% difference was attributed to decomposition of the citrate coating. The estimated surface density of 219 
citric acid is 3.3[Doesn’t this need some unit?]/nm2. Using a molecular diameter of citric acid of 0.57 nm 220 
[41], the coverage of citrate-coating was estimated to be 77% [42]. 221 
3.3 26Al in dosing material 222 
Table 1 shows the ratio of 26Al/27Al obtained by AMS and the calculated fraction of 26Al in samples. The 223 
26Al/27Al ratio in dosing material sample Al2O3-1 was 1.41×10-9. The number of 26Al in Al2O3-1 was 224 
1.26×1011 atoms. The 26Al/27Al ratio in Al2O3-2 was 1.20×10-9. It contained 1.07×1011 26Al atoms. The 225 
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average number of 26Al atoms in Al2O3-1 and Al2O3-2 was 1.16×1011. Both of them were 10 µL aliquots 226 
of 100-fold diluted dosing material. So the dosing material had an average number concentration of 227 
1.16×1015 26Al /ml. The treated rat received 0.4 ml of the dosing material, corresponding to 4.65×1014 26Al 228 
atoms or 0.383 nCi. It was 2.4 times the planned dose.  229 
3.4 26Al in tissue samples 230 
The 26Al/ 27Al ratio in liver-1 sample (38.7 mg) was 2.41×10-9. The liver-1 sample contained 2.15×1011 231 
26Al atoms. The liver weight from dosed and control rats was around 16.3 grams so the total liver would 232 
contain 9.06×1013 26Al atoms or 7.47×10-2 nCi, corresponding to 19.5% of the dose. The 26Al/27Al ratio in 233 
liver-2 (35.9 mg) was 7.61×10-13. The liver-2 sample contained 6.78×107 26Al atoms so the total liver of 234 
control rat would contain 3.08×1010 26Al atoms or 2.54×10-5 nCi, more than 3 orders of magnitude less 235 
than the liver from the dosed rat. The weight of liver was about 3.2% of the rat’s weight and contained 236 
19.5% of dose, showing accumulation of the nanoalumina in the liver. 237 
The 26Al/27Al ratio in the brain-1 sample was 5.99×10-11. Brain-1 sample (757.1 mg) contained 5.35×109 238 
26Al atoms.  The average weight of a rat’s brain is 1.86 gram so the total brain would contain 1.31 239 
×101026Al atoms or 1.08×10-5 nCi, about 0.003% of the dosing material. The 26Al/27Al ratio in brain-2 was 240 
5.01×10-11.  Brain-2 sample (738 mg) contained 4.47×109 26Al atoms so the total brain from control rat 241 
contained 1.13 ×1010 nCi 26Al atoms or 9.27 ×10-6 nCi.  242 
The 26Al/27Al background for samples without 26Al was around 10-14 in the AMS measurements. So the 243 
high 26Al/27Al ratio in the control rat suggests that some low-level contamination happened during 244 
infusion or surgery. We can’t compare the actual difference between the 26Al in (brains?) from dosed and 245 
control rats.  However, the 0.003% of dosing material can be considered as the upper limit of 26Al in the 246 
brain from dosed rats. It indicates only a very small amount (if any) of the 26Al got incorporated into the 247 
brain since the nanoalumina did not cross the blood-brain barrier to enter brain parenchyma. 248 
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The 26Al/27Al ratio in bone-1 sample was 4.62×10-12. The bone-1 tissue (52 mg) contained 4.12×108 26Al 249 
atoms.  The total rat skeletal weight is about of 5% of body weight (25 gram). So the total skeletal system 250 
would contain 1.98×1011 26Al atoms or 1.63×10-4 nCi, 0.043% of the dose. The bone-2 (50.8 mg) 251 
contained 7.52×108 26Al atoms, translating to a total rat skeletal content of 3.05×10-4 nCi. The control rat 252 
bone had higher radioactivity in the bone than the dosed animal. The unexpected result may be from the 253 
same low level contamination that affected the brain. The 0.043% of dosing material was used as the 254 
upper limit and indicates only small amount (if any) of the 26Al got incorporated into the brain. In the 255 
typical mammal, 60% of the body burden of Al is in the skeletal system and only 3% in the liver [43]. The 256 
high concentration of 26Al in liver and low concentration in bone suggests that the 26Al from the 257 
nanoalumina is difficult to dissolve and redistribute into bone. 258 
3.5 14C in dosing material 259 
Table 2 shows the ratio of 14C/12C obtained by AMS and the calculated sample activity. The 14C/12C in 260 
CA-1, CA-2, and CA-3 samples was 10353, 9342, and 8359, giving an average number of 1.1× 109 14C 261 
atoms in the three aliquots. They were 10 µL aliquots of 10-fold diluted dosing material so the dosing 262 
material had number concentration of 1.1× 1012  14C atoms/mL. The rat got 0.4 mL of the dosing material, 263 
corresponding to 4.40×1011 14C atoms or 4.56×10-2 nCi. It was 28.5% of the planned dose.  264 
3.6 14C in tissue samples 265 
Because 14C is ubiquitous in air, water and food, it inevitably enters the animal to become stored and form 266 
the 14C background. The typical ratio 14C/12C of mammal’s tissue sample via previous AMS 267 
measurements is around 1250. It is very close to a value reported in literature [44]. However, the precise 268 
ratio in each organ does vary, so we used the ratios in the control rat as our background.  269 
After subtracting the average 14C/12C ratio background (1437.5) from Liver-2 and Liver-3 samples, the 270 
actual 14C/12C ratio in liver-1 sample was 607.5. The typical carbon percent in liver is 15 wt%. There are 271 
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1.23×1023 12C atoms in total liver (16.3 grams). The calculated 14C in the total liver of the dosed rat was 272 
7.45×1010 or 7.72×10-3 nCi, 16.9% of the dose. The 14C of the coating material concentrated in the liver of 273 
the dosed rat, but the differences between the dosed rat and the controls was not as large as those for the 274 
core material, 26Al.  275 
The 14C/12C ratio (1261) from Brain-2 of the control rat was used as the background. After subtracting 276 
background, the 14C/12C in brain-1 sample is 22. The difference is larger than one standard deviation of 277 
the measured value so there was some higher amount of 14C in brain of the dosed rat than the control rat in 278 
a statistically significant sense. The typical carbon percent in brain is 15 wt%. There are 1.40×1022 12C 279 
atoms in the total brain (1.86 grams). The total brain would contain 3.08×108 14C atoms or 3.19×10-5 nCi, 280 
0.07% of the dosage. For the Brain-3 sample, the 14C/12C ratio is much higher than brain-2 sample, even 281 
brain-1. The contamination may have come from a previous sample with high ratio of 14C/12C that was 282 
dried in the vacuum centrifuge. This seemed highly likely since a check of the records at the PRIME  Lab 283 
showed that the one sample was dried with a batch of samples that had 14C/12C ratios 100 times higher. 284 
Thus, it was considered safe to discard this result.  285 
After subtracting the average 14C/12C ratio background (1412.5) from Bone-2 and Bone-3 samples, the 286 
actual ratio of 14C/12C in bone-1 sample was 76.5. The typical carbon percent in bone was around 12% 287 
[45]. There are 1.51×1023 12C atoms in total bone (25 grams). The total bone would contain 1.16×1010 14C 288 
atoms or 1.20×10-3 nCi, 2.63% of the dosage. The bone from the dosed rat had higher 14C than that from 289 
the control rat. 290 
3.7 The ratio of coating/core and material balance 291 
The ratio between 14C/26Al in different organs and the mass distribution are shown in Table 3. In the 292 
dosing material, the average numbers of 26Al and 14C atoms were 4.65×1014 and 4.40×1011 respectively.   293 
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The 14C/26Al was 9.46×10-4. The total recovered 26Al and 14C from liver, brain and bone are 19.5% and 294 
19.6% of the dosing material respectively.  295 
The numbers of isotope atoms in the dosed liver were: 26Al = 9.06×1013 and 14C = 7.45×1010. The 14C/26Al 296 
in liver of the dosed rat was 8.22×10-4, around 87% of the ratio in the dosing material. The citrated coating 297 
entering the liver (19.5% of dosage) partially dissociated from the nanoalumina, and would have been 298 
available to redistribute into organs such as the brain and bone.  299 
The average numbers of isotope atoms in brain were: 26Al <1.31×1010 and 14C = 3.08×108, for a 14C/26Al 300 
ratio > 2.35×10-2. The average numbers of isotope atoms in bone were: 26Al <1.98×1011 and 14C = 301 
1.16×1010, for a 14C/26Al calculated ratio > 5.81×10-2. Both of these ratios are much higher than that of the 302 
dosing material. The reason is that 14C preferentially accumulated in brain (0.07%) and bone (2.63%) 303 
compared to the levels of 26Al in these two organs (0.003% and 0.043%, respectively). This finding 304 
suggests that some of the citrate coating dissociated from the nanoalumina’s surface and then redistributed 305 
to organs such as the brain and bone.  306 
 307 
4. Conclusions 308 
The core and surface coatings of a complex engineered nanoparticle have been tracked during biological 309 
exposure to the rat using rare isotope labels detected by AMS. The alumina core was tracked using 26Al 310 
and the citrate coating was tracked using 14C. Comparison of the rare isotope levels and their ratios, 311 
14C:26Al, in different organs demonstrated the relative stability of the two CENP components. The amount 312 
of 26Al in the liver of the dosed rat was higher than that of control rats. The amounts of 26Al in brain and 313 
bone of the dosed rat were similar to those of the control rat. It suggests the nanoalumina accumulated, 314 
and persisted in the liver 30 days after infusion. The amounts of 14C in the liver, bone, and brain of the 315 
dosed rat were also higher than those of the control rats. However, the 14C/26Al ratios differed between 316 
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liver, brain, and bone. Slightly less coating material went to the liver compared to the core material and its 317 
levels were significantly higher in brain and bone compared to the core material. Some of the citrate 318 
coating dissociated from the nanoparticle surfaces and redistributed to organs such as the brain and bone. 319 
AMS methodology provides a new opportunity to characterize the biodistribution of complex engineering 320 
nanomaterials. 321 
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